Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab

Clin Exp Rheumatol. 2010 Jul-Aug;28(4 Suppl 60):S102. Epub 2010 Sep 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Behcet Syndrome / drug therapy*
  • Humans
  • Infliximab
  • Male
  • Treatment Failure
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab